Talzenna for gBRCAm HER2-negative Locally Advanced or Metastatic Breast Cancer

News
Article

Talzenna Product Image

Talzenna (talazoparib, Pfizer)

Indications: Adult Patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) HER2-negative locally advanced or metastatic breast cancer.

Dosage: 1 mg singly oral daily dose until disease progression or unacceptable toxicity occurs

Contraindications: None

Click here for more prescribing information

Newsletter

Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.

Recent Videos
© 2025 MJH Life Sciences

All rights reserved.